Sime Armoyan Sells 550,000 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 550,000 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of C$6.20, for a total value of C$3,410,000.00.

Sime Armoyan also recently made the following trade(s):

• On Monday, March 17th, Sime Armoyan sold 92,200 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.15, for a total value of C$567,030.00.
• On Thursday, March 13th, Sime Armoyan sold 1,100 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.10, for a total value of C$6,710.00.
• On Tuesday, March 4th, Sime Armoyan purchased 17,600 shares of Knight Therapeutics stock. The stock was acquired at an average cost of C$5.48 per share, for a total transaction of C$96,488.48.

Knight Therapeutics Stock Down 1.4 %

Shares of TSE:GUD opened at C$6.18 on Friday. The stock’s 50-day moving average price is C$5.68 and its two-hundred day moving average price is C$5.58. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. Knight Therapeutics Inc. has a 12-month low of C$5.09 and a 12-month high of C$6.45. The firm has a market cap of C$625.11 million, a price-to-earnings ratio of -20.63, a PEG ratio of -1,013.50 and a beta of 0.50.

Analyst Ratings Changes

Separately, Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. Two analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Strong Buy” and an average price target of C$7.08.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.